Because research options for IC/BPS are rare, your patients who continue to suffer from pain associated with IC/BPS may be interested in joining a phase 2 clinical study that will investigate the safety and efficacy of a new, potential pain management option.
The study will evaluate IW-3300, a novel, rectally administered foam designed to target the inhibition of pain receptors in the colon and modify pain relief in the bladder. Based upon phase 1 study data, IW-3300 appears to be well tolerated.
Patients in the study will receive…
- The investigational drug (approx. 67%) or placebo (approx. 33%)
- Close study-related care and monitoring
- Compensation for travel and expenses related to study participation, if needed
If you have patients you believe would be interested in this study, please fill out the form below.